BioLine RX Ltd
TASE:BLRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sunshine Global Circuits Co Ltd
SZSE:300739
|
CN |
|
A
|
Aerospace CH UAV Co Ltd
SZSE:002389
|
CN |
BioLine RX Ltd
Stock-Based Compensation
BioLine RX Ltd
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioLine RX Ltd
TASE:BLRX
|
Stock-Based Compensation
$396k
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-10%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Stock-Based Compensation
$845k
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-8%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Stock-Based Compensation
$1.8m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
1%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Stock-Based Compensation
$12m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Stock-Based Compensation
$2.6m
|
CAGR 3-Years
14%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Stock-Based Compensation
$2.7m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-4%
|
|
BioLine RX Ltd
Glance View
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
See Also
What is BioLine RX Ltd's Stock-Based Compensation?
Stock-Based Compensation
396k
USD
Based on the financial report for Dec 31, 2025, BioLine RX Ltd's Stock-Based Compensation amounts to 396k USD.
What is BioLine RX Ltd's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
-10%
Over the last year, the Stock-Based Compensation growth was -65%. The average annual Stock-Based Compensation growth rates for BioLine RX Ltd have been -43% over the past three years , and -10% over the past ten years .
